Drug Profile


Latest Information Update: 10 Dec 2003

Price : $50

At a glance

  • Originator Asahi Breweries
  • Class Antineoplastics; Coenzymes; Pterins; Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 10 Dec 2003 Discontinued - Preclinical for Atherosclerosis in Japan (unspecified route)
  • 13 Mar 2000 No-Development-Reported for Atherosclerosis in Japan (Unknown route)
  • 03 Mar 1997 A pharmacodynamic study has been added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top